273 related articles for article (PubMed ID: 30254189)
1. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
2. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
10. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
[TBL] [Abstract][Full Text] [Related]
11. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery as a primary treatment for metastatic skull base alveolar soft part sarcoma: a case report.
Shinya Y; Hasegawa H; Kawashima M; Shin M; Takahashi W; Kobayashi H; Saito N
Acta Neurochir (Wien); 2021 Feb; 163(2):351-355. PubMed ID: 32686069
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
Jung KS; Lee SJ; Park SH; Lee JL; Lee SH; Lim JY; Kang JH; Lee S; Rha SY; Lee KH; Kim HY; Lim HY
Cancer Res Treat; 2018 Apr; 50(2):488-494. PubMed ID: 28546525
[TBL] [Abstract][Full Text] [Related]
14. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.
Yoshihiro T; Tsuchihashi K; Nio K; Arita S; Nakano T; Yasumatsu R; Jiroumaru R; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
Medicine (Baltimore); 2017 Nov; 96(44):e8470. PubMed ID: 29095301
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
20. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Samuels BL; Chawla SP; Somaiah N; Staddon AP; Skubitz KM; Milhem MM; Kaiser PE; Portnoy DC; Priebat DA; Walker MS; Stepanski EJ
Cancer; 2017 Dec; 123(23):4640-4647. PubMed ID: 28832986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]